HIGHLIGHTS

AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development
Samir N. Khleif, James H. Doroshow, and William N. Hait; for the AACR-FDA-NCI Cancer Biomarkers Collaborative

ADAM-17: A Target to Increase Chemotherapeutic Efficacy in Colorectal Cancer?
Adam M. Lee and Robert B. Diasio

New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK
Giorgia Zadra, Carmen Priolo, Akash Patnaik, and Massimo Loda

Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
Christine A. Pratilas and David B. Solit

The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment
Ivor Caro and Jennifer A. Low

BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood
Natalia Bednarz, Elke Eltze, Axel Semjonow, Michael Rink, Antje Andreas, Lennart Mulder, Juliane Hannemann, Margit Fisch, Klaus Pantel, Heinz-Ulrich G. Weier, Krzysztof P. Bielawski, and Burkhard Brandt

Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer
Atsuko Kitamura, Waki Hosoda, Eiichi Sasaki, Tetsuya Mitsudomi, and Yasushi Yatabe

Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome
Göran Jönsson, Christian Busch, Stian Knappskog, Jürgen Geisler, Hrvoje Miletic, Markus Ringnér, Johan R. Lillegaard, Åke Borg, and Per Eystein Lønning

A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas
Dorine A. Bax, Alan Mackay, Suzanne E. Little, Diana Carvalho, Marta Viana-Pereira, Narinder Tamber, Anita E. Grigoriadis, Alan Ashworth, Rui M. Reis, David W. Ellison, Safa Al-Sarraj, Darren Hargrave, and Chris Jones

Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer
Joan N. Kyula, Sandra Van Schaeybroeck, Joanne Doherty, Catherine S. Fenning, Daniel B. Longley, and Patrick G. Johnston

The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo

Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy
Darya Alizadeh, Leye Zhang, Christine E. Brown, Omar Farrukh, Michael C. Jensen, and Behnam Badie
Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR
Kimberly Laskie Ostrow, Mohammad O. Hoque, Myriam Loyo, Marianna Brait, Alissa Greenberg, Jill M. Siegfried, Jennifer R. Grandis, Autumn Gaither Davis, William L. Bigbee, William Rom, and David Sidransky

Diverse Associations between ESRI Polymorphism and Breast Cancer Development and Progression
Shian-ling Ding, Jyh-Cherng Yu, Shou-Tung Chen, Giu-Cheng Hsu, Huan-Ming Hsu, Jar Yi Ho, Yu Hsin Lin, Chien-Ching Chang, Cathy S.J. Fann, Chun-Wen Cheng, Pei-Ei Wu, and Chen-Yang Shen

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide, Patricia M. LoRusso, Magi Khalil, Elaina M. Gartner, Divis Khaira, Denis Soulieres, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, Gabriella L. Mariani, Tiziana Usari, and Susan M. Domchek

Results from a Phase I Clinical Study of the Novel II-Key/HER-2/neu (776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer
Sonia A. Perez, Nikoletta L. Kallinteris, Stratos Bisias, Panagiotis K. Tzonis, Katerina Georgakopoulou, Marighoula Varla-Leftherioti, Eric von Hofe, and Constantin N. Baxevanis

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
ABOUT THE COVER

High-grade gliomas are among the deadliest of human cancers and appropriate glioma mouse models that are conveniently applicable for therapy-intervention studies can contribute to the finding of more efficacious treatments. Following the intracranial injection of lentiviral Cre-recombinase vectors into $\text{LoxP}$-conditional $\text{p53}$ (or $\text{pten}$); $\text{Ink4a}/\text{Arf}$/ $\text{K-Ras}^{v12}$; $\text{LucR}$ mice, noninvasively visible high-grade gliomas arise with a short tumor latency that show features commonly found in human high-grade glioma, such as a high mitotic index, nuclear atypia, pseudopalisading necrosis, and giant cell formation. For further details, please see the article by de Vries and colleagues on page 3431 of this issue.
Clinical Cancer Research

16 (13)

Clin Cancer Res 2010;16:3297-3519.

Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/13

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications</td>
</tr>
<tr>
<td>Subscriptions</td>
<td>Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications</td>
</tr>
<tr>
<td></td>
<td>Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>